The goal of this pilot randomized clinical trial is to look into the efficacy of concentrated bone marrow aspirate (cBMA) in improving post traumatic osteoarthritis (PTOA) symptoms in patients undergoing revision anterior cruciate ligament reconstruction surgery. The main questions it aims to answer are whether clinical outcomes, such as pain, are improved in patients who get cBMA with surgery, if there is a change in circulating markers of inflammation and what part of the cellular and molecular composition of cBMA may explain its effects.
Males and Females
Age 18 to 55
Previous unilateral ACLR (Anterior Cruciate Ligament Reconstruction) within the last 5 years, and identified as having experienced failure of the primary ACLR
Scheduled to have a revision ACLR surgery, with any graft type (including patellar tendon, hamstring, quad or allograft)
History of inflammatory arthritis or joint sepsis
Prior or concurrent total or sub-total meniscectomy
Prior or present avascular necrosis of the index knee
Oral or intra-articular corticosteroid injection within 3 months
Hospital for Special Surgery, New York
Lead sponsor
Emory University
Collaborator
Arthritis Foundation
Collaborator